Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: Speciation of arsenic metabolites in serum and urine

Yasuomi Fukai, Miyuki Hirata, Mayumi Ueno, Naoaki Ichikawa, Hikaru Kobayashi, Hiroshi Saitoh, Teruaki Sakurai, Kenji Kinoshita, Toshikazu Kaise, Shin Ohta

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The pharmacokinetics of arsenic species in a Japanese patient with relapsed acute promyelocytic leukemia (APL) treated with arsenic trioxide at a daily dose of 0.08 mg/kg was investigated. After achieving complete remission on Day 35 during the induction therapy of arsenic trioxide, we collected the serum and urine samples on Days 4 and 5 during the consolidation therapy of arsenic trioxide. The concentrations of inorganic arsenic and the methylated metabolites in serum and urine were measured by HPLC/ICP-MS. The patient restricted taking the seafood for 3 d before the start of administration and during the sampling period in order to avoid the influence of arsenic derived from seafood. Arsenite (AsIII), methylarsonic acid (MMAsV), and dimethylarsinic acid (DMAsV) were detected in serum and urine. The total concentration of AsIII, MMAsV and DMAsV in serum ranged from 18 to 41 μg/l (240-547 nM) during 24 h on Day 4. The amount of total arsenic (AsIII+MMAsV+DMAsV) in urine was 4464 μg/d on Day 4. These results suggest that not the micro-molar but the nano-molar order of arsenic in serum is sufficient to produce the therapeutic effect on APL cells.

Original languageEnglish
Pages (from-to)1022-1027
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume29
Issue number5
DOIs
Publication statusPublished - May 1 2006

Fingerprint

Acute Promyelocytic Leukemia
Arsenic
Pharmacokinetics
Urine
Seafood
Serum
Cacodylic Acid
Therapeutic Uses
High Pressure Liquid Chromatography
Clinical Studies
arsenic trioxide
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient : Speciation of arsenic metabolites in serum and urine. / Fukai, Yasuomi; Hirata, Miyuki; Ueno, Mayumi; Ichikawa, Naoaki; Kobayashi, Hikaru; Saitoh, Hiroshi; Sakurai, Teruaki; Kinoshita, Kenji; Kaise, Toshikazu; Ohta, Shin.

In: Biological and Pharmaceutical Bulletin, Vol. 29, No. 5, 01.05.2006, p. 1022-1027.

Research output: Contribution to journalArticle

Fukai, Yasuomi ; Hirata, Miyuki ; Ueno, Mayumi ; Ichikawa, Naoaki ; Kobayashi, Hikaru ; Saitoh, Hiroshi ; Sakurai, Teruaki ; Kinoshita, Kenji ; Kaise, Toshikazu ; Ohta, Shin. / Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient : Speciation of arsenic metabolites in serum and urine. In: Biological and Pharmaceutical Bulletin. 2006 ; Vol. 29, No. 5. pp. 1022-1027.
@article{667cb0617a904055b55901dda945b4d0,
title = "Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: Speciation of arsenic metabolites in serum and urine",
abstract = "The pharmacokinetics of arsenic species in a Japanese patient with relapsed acute promyelocytic leukemia (APL) treated with arsenic trioxide at a daily dose of 0.08 mg/kg was investigated. After achieving complete remission on Day 35 during the induction therapy of arsenic trioxide, we collected the serum and urine samples on Days 4 and 5 during the consolidation therapy of arsenic trioxide. The concentrations of inorganic arsenic and the methylated metabolites in serum and urine were measured by HPLC/ICP-MS. The patient restricted taking the seafood for 3 d before the start of administration and during the sampling period in order to avoid the influence of arsenic derived from seafood. Arsenite (AsIII), methylarsonic acid (MMAsV), and dimethylarsinic acid (DMAsV) were detected in serum and urine. The total concentration of AsIII, MMAsV and DMAsV in serum ranged from 18 to 41 μg/l (240-547 nM) during 24 h on Day 4. The amount of total arsenic (AsIII+MMAsV+DMAsV) in urine was 4464 μg/d on Day 4. These results suggest that not the micro-molar but the nano-molar order of arsenic in serum is sufficient to produce the therapeutic effect on APL cells.",
author = "Yasuomi Fukai and Miyuki Hirata and Mayumi Ueno and Naoaki Ichikawa and Hikaru Kobayashi and Hiroshi Saitoh and Teruaki Sakurai and Kenji Kinoshita and Toshikazu Kaise and Shin Ohta",
year = "2006",
month = "5",
day = "1",
doi = "10.1248/bpb.29.1022",
language = "English",
volume = "29",
pages = "1022--1027",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient

T2 - Speciation of arsenic metabolites in serum and urine

AU - Fukai, Yasuomi

AU - Hirata, Miyuki

AU - Ueno, Mayumi

AU - Ichikawa, Naoaki

AU - Kobayashi, Hikaru

AU - Saitoh, Hiroshi

AU - Sakurai, Teruaki

AU - Kinoshita, Kenji

AU - Kaise, Toshikazu

AU - Ohta, Shin

PY - 2006/5/1

Y1 - 2006/5/1

N2 - The pharmacokinetics of arsenic species in a Japanese patient with relapsed acute promyelocytic leukemia (APL) treated with arsenic trioxide at a daily dose of 0.08 mg/kg was investigated. After achieving complete remission on Day 35 during the induction therapy of arsenic trioxide, we collected the serum and urine samples on Days 4 and 5 during the consolidation therapy of arsenic trioxide. The concentrations of inorganic arsenic and the methylated metabolites in serum and urine were measured by HPLC/ICP-MS. The patient restricted taking the seafood for 3 d before the start of administration and during the sampling period in order to avoid the influence of arsenic derived from seafood. Arsenite (AsIII), methylarsonic acid (MMAsV), and dimethylarsinic acid (DMAsV) were detected in serum and urine. The total concentration of AsIII, MMAsV and DMAsV in serum ranged from 18 to 41 μg/l (240-547 nM) during 24 h on Day 4. The amount of total arsenic (AsIII+MMAsV+DMAsV) in urine was 4464 μg/d on Day 4. These results suggest that not the micro-molar but the nano-molar order of arsenic in serum is sufficient to produce the therapeutic effect on APL cells.

AB - The pharmacokinetics of arsenic species in a Japanese patient with relapsed acute promyelocytic leukemia (APL) treated with arsenic trioxide at a daily dose of 0.08 mg/kg was investigated. After achieving complete remission on Day 35 during the induction therapy of arsenic trioxide, we collected the serum and urine samples on Days 4 and 5 during the consolidation therapy of arsenic trioxide. The concentrations of inorganic arsenic and the methylated metabolites in serum and urine were measured by HPLC/ICP-MS. The patient restricted taking the seafood for 3 d before the start of administration and during the sampling period in order to avoid the influence of arsenic derived from seafood. Arsenite (AsIII), methylarsonic acid (MMAsV), and dimethylarsinic acid (DMAsV) were detected in serum and urine. The total concentration of AsIII, MMAsV and DMAsV in serum ranged from 18 to 41 μg/l (240-547 nM) during 24 h on Day 4. The amount of total arsenic (AsIII+MMAsV+DMAsV) in urine was 4464 μg/d on Day 4. These results suggest that not the micro-molar but the nano-molar order of arsenic in serum is sufficient to produce the therapeutic effect on APL cells.

UR - http://www.scopus.com/inward/record.url?scp=33646447206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646447206&partnerID=8YFLogxK

U2 - 10.1248/bpb.29.1022

DO - 10.1248/bpb.29.1022

M3 - Article

C2 - 16651738

AN - SCOPUS:33646447206

VL - 29

SP - 1022

EP - 1027

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -